CBN vs melatonin

CBN and melatonin sit next to each other on the shelf and get compared constantly. They have almost nothing in common. One is a cannabinoid that forms when THC ages. The other is a hormone your own brain produces every night. Here is what each one is, how it is made, and what the trials actually measured.

What is each one?

Cannabinol (CBN) was first isolated in 1896 and occurs in hemp and cannabis "in small amounts". It is "a degradation product of delta-9 THC" and is "generally considered non-intoxicating", according to the Montana Cannabis Control Division (Montana CCD, January 2025).

Melatonin "is a hormone that your brain produces in response to darkness", per the National Center for Complementary and Integrative Health (NCCIH). Light at night can block its production. In the United States it is sold as a dietary supplement; several other countries require a prescription.

How is each one made?

This is the first real difference, and it matters for the federal hemp rule.

CBN forms naturally when THC is exposed to heat and oxygen over time. Old, poorly stored biomass has more of it. A processor can make non-synthetic CBN by heating THC distillate in open air with no reagents. But hemp has little THC to start with, so, in Montana's words, "any hemp derived CBN (distillate or isolate) is typically chemically synthesized from CBD to be financially profitable", and a manufacturer's COA "does not adequately demonstrate the synthetic or non-synthetic status of CBN" because it does not show the production method (Montana CCD). Montana prohibits synthetically derived cannabinoids, including converted CBN, as of May 22, 2023.

Federally, the amended hemp definition excludes cannabinoids "synthesized or manufactured outside the plant" (7 U.S.C. 1639o amendment notes). Public Law 119-103 delayed that clause to December 11, 2026, while the narrower exclusion for cannabinoids the plant cannot naturally produce lands November 12, 2026 (GovInfo). CBN is a cannabinoid the plant does produce, so the question for any CBN product after December 11 is the production pathway, which means asking the supplier for a process attestation, not just a COA.

Melatonin supplements, by contrast, are "most often" synthesized, and can also be sourced from animals or microorganisms (NCCIH). There is no legal question attached to the pathway.

What is a typical serving?

Current CBN products run 15 to 20 mg. The Slumber catalog lists a 15 mg CBN isolate gummy and 20 mg CBN softgels, both marked zero melatonin (Slumber catalog). The main published trial used 20 mg nightly.

Melatonin gummies on the U.S. market were labeled at 1 to 10 mg per serving in a 2023 JAMA analysis of 25 products (Cohen et al., 2023). NCCIH gives no milligram recommendation and notes "uncertainties about what dose to use and when to give it".

How fast does each one act?

For melatonin, the pharmacokinetics are published: after an immediate-release oral dose, "Tmax was approximately 50 min", half-life was about 45 minutes, and oral bioavailability was "approximately 15%" with a range of 9 to 33% across studies (Harpsoe et al., 2015). The 2018 trial NCCIH cites gave it one hour before the target bedtime.

For CBN, no human pharmacokinetic study was located for this page. The sleep trial dosed nightly for seven nights and reported outcomes, not blood levels. TODO: add onset and half-life when a CBN pharmacokinetic paper is published.

What did the trials measure?

The CBN evidence is one trial. Bonn-Miller and colleagues randomized adults aged 18 to 55 who rated their sleep as "poor" or "very poor" to placebo, 20 mg CBN, or 20 mg CBN with 10, 20 or 100 mg CBD for seven consecutive nights. In the 293-person analysis, "20 mg CBN demonstrated a nonsignificant but potentially meaningful effect on sleep quality", the primary endpoint, while the CBN group showed "reduced nighttime awakenings and overall sleep disturbance" relative to placebo "with no impact on daytime fatigue". Adding CBD "did not positively augment" the CBN result (Bonn-Miller et al., 2023). The study was sponsored by Canopy Growth, and several authors are company employees. Read it as a promising first trial, not a settled result, and not as evidence about any retail product.

The melatonin evidence is broad. NCCIH summarizes a 2018 trial of 307 people with a delayed sleep schedule who "fell asleep an average of 34 minutes earlier" with melatonin plus a fixed bedtime, and a 2016 review of 52 people who fell asleep "about 22 minutes" faster than with placebo (NCCIH). The effects are modest and the page says long-term effects "are unclear".

Who should check with a clinician first?

For melatonin, NCCIH is specific. Parents "should first speak with a health care provider" before giving it to children. There is "a lack of research on the safety" in pregnancy and breastfeeding. It "may stay active in older people longer" and cause daytime drowsiness. People taking blood thinners need clinician supervision. The CDC estimated 11,000 emergency department visits from 2019 to 2022 for unsupervised melatonin ingestion by children five and under, so storage matters (NCCIH).

For CBN, the honest answer is that no safety data exist for pregnancy, breastfeeding, children, or use alongside other drugs. The single trial enrolled adults 18 to 55. FDA's cannabis page does not mention CBN, but it says unapproved cannabinoid products have not been evaluated for "how they could interact with other drugs" (FDA). If you take prescription drugs, talk to a pharmacist before adding CBN to your routine.

Should you stack them?

Not without a reason. In the CBN trial, adding 10 to 100 mg of CBD did not improve on 20 mg CBN alone, which argues against reflexive stacking. Current CBN products from the supplier catalog are built "zero melatonin" on purpose.

Melatonin has its own label-accuracy problem that stacking compounds. In the 2023 JAMA analysis, "22 of 25 products (88%) were inaccurately labeled" and measured content "ranged from 74% to 347% of the labeled quantity". Five of those products also declared CBD, at 10 to 30 mg (Cohen et al., 2023). A gummy that stacks two ingredients, each with uncertain content, is two unknowns in one bite.

The practical approach: pick one, use it at a fixed time for two weeks, keep a simple sleep log, and bring that log to a clinician if you want to change anything. A sleep routine (fixed bedtime, dark room, no screens) is the part both of these are meant to support, not replace.